Entity

Time filter

Source Type

Chengjiang, China

Zhang C.,Nanjing Medical University | Yang X.,Nanjing Medical University | Zhang Q.,Bengbu Medical College | Guo Q.,Taizhou University | And 12 more authors.
Tumor Biology | Year: 2014

Radiotherapy is the main therapy for inoperable and locally advanced esophageal squamous cell carcinoma (ESCC). However, radioresistance in ESCC remains a challenge. The aim of this study is to investigate the radiosensitizing effects of STAT3 inhibitor NSC74859 on ESCC and explore the underlying mechanisms. ECA109 and TE13 cells were exposed to hypoxia, and treated with NSC74859 or radiation, alone or in combination. Cell proliferation, survival, apoptosis, and double-stranded DNA breaks (DSBs) were examined. Nude mice model of ECA109 xenograft was treated with radiation and/or NSC74859. The levels of STAT3, p-STAT3, HIF-1α, and VEGF were detected by Western blot analysis. NSC74859 efficiently radiosensitized ESCC cells and xenografts in nude mice, and inhibited hypoxia-/radiation-induced activation of STAT3 and upregulation of HIF-1α and VEGF expression. NSC74859 confers radiosensitivity in ESCC via the inhibition of STAT3 activation and the downregulation of HIF-1α and VEGF expression. NSC74859 may become a promising radiosensitizer for ESCC radiotherapy. © 2014, International Society of Oncology and BioMarkers (ISOBM). Source


Mao W.,Jiangyin Peoples Hospital | Mao W.,Sun Yat Sen University | Guan X.,Sun Yat Sen University | Guan X.,State Key Laboratory of Oncology in South China | And 11 more authors.
Chemotherapy | Year: 2011

Objective: This phase II study was designed to evaluate the effects of vinorelbine (VRL) and capecitabine (CAP) as second-line combination chemotherapy in patients with advanced breast cancer (ABC) previously treated with anthracyclines and/or taxanes. Methods: Treatment consisted of VRL 25 mg/m 2 administered on days 1 and 8 of a 21-day treatment cycle, along with oral CAP 825 mg/m2 twice daily for 14 days, followed by 7 days of rest. Results: 50 patients were enrolled and 48/50 (96.0%) patients were assessable for response. The median time to progression (TTP) and overall survival (OS) of the patients were 5.0 (95% confidence interval, CI, 2.1-7.9 months) and 12.0 months (95% CI, 8.0-16.0 months), respectively. The objective response rate was 26.0% (95% CI, 13.8-38.2%) with 1 confirmed complete response and 12 partial responses. The most frequent hematological adverse event was neutropenia of grade 3 and 4 in 5 (10.4%) and 2 patients (4.2%), respectively. Grade 3 stomatitis, asthenia, and diarrhea were observed in 1 (2.1%), 2 (4.2%) and 3 (6.3%) patients, respectively. Conclusion: The combination of VRL and CAP is feasible as second-line chemotherapy in patients with ABC previously treated with anthracyclines and/or taxanes, with efficacy being comparable to other available combination regimens. Copyright © 2011 S. Karger AG. Source


Xi B.,Shandong University | Huang Y.,Tianjin Medical University | Li S.,Shandong University | Zheng R.,Jiangyin Peoples Hospital | And 5 more authors.
British Journal of Nutrition | Year: 2015

A number of prospective cohort studies have investigated the associations between consumption of sugar-sweetened beverages (SSB) and the risk of hypertension, CHD and stroke, but revealed mixed results. In the present study, we aimed to perform a dose-response meta-analysis of these prospective studies to clarify these associations. A systematic literature search was conducted using the PubMed and Embase databases up to 5 May 2014. Random- or fixed-effects models were used to calculate the pooled relative risks (RR) with 95% CI for the highest compared with the lowest category of SSB consumption, and to conduct a dose-response analysis. A total of six prospective studies (240 726 participants and 80 411 incident cases of hypertension) from four publications on hypertension were identified. A total of four prospective studies (194 664 participants and 7396 incident cases of CHD) from four publications on CHD were identified. A total of four prospective studies (259 176 participants and 10 011 incident cases of stroke) from four publications on stroke were identified. The summary RR for incident hypertension was 1·08 (95% CI 1·04, 1·12) for every additional one serving/d increase in SSB consumption. The summary RR for incident CHD was 1·17 (95% CI 1·10, 1·24) for every serving/d increase in SSB consumption. There was no significant association between SSB consumption and total stroke (summary RR 1·06, 95% CI 0·97, 1·15) for every serving/d increase in SSB consumption. The present meta-analysis suggested that a higher consumption of SSB was associated with a higher risk of hypertension and CHD, but not with a higher risk of stroke. © The Authors 2015. Source


Xu K.,Nanjing Medical University | Liu X.,Nanjing Medical University | Yang F.,Nanjing Medical University | Cui D.,Nanjing Medical University | And 4 more authors.
PLoS ONE | Year: 2013

A meta-analysis was performed to assess the association between the PAI-1 -675 4G/5G polymorphism and susceptibility to diabetes mellitus (DM), diabetic nephropathy (DN), diabetic retinopathy (DR) and diabetic coronary artery disease (CAD). A literature-based search was conducted to identify all relevant studies. The fixed or random effect pooled measure was calculated mainly at the allele level to determine heterogeneity bias among studies. Further stratified analyses and sensitivity analyses were also performed. Publication bias was examined by the modified Begg's and Egger's test. Twenty published articles with twenty-seven outcomes were included in the meta-analysis: 6 studies with a total of 1,333 cases and 3,011 controls were analyzed for the PAI-1 -675 4G/5G polymorphism with diabetes risk, 7 studies with 1,060 cases and 1,139 controls for DN risk, 10 studies with 1,327 cases and 1,557 controls for DR and 4 studies with 610 cases and 1,042 controls for diabetic CAD risk respectively. Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models. Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated. This conclusion warrants confirmation by further studies. © 2013 Xu et al. Source


Xu M.-F.,Jiangyin Peoples Hospital
Journal of Acupuncture and Tuina Science | Year: 2013

Objective: To observe the clinical efficacy and safety of acupuncture plus auricular point sticking in treating melasma. Methods: Forty-three eligible subjects with melasma were intervened by acupuncture plus auricular point sticking, 10 times as a treatment course, with an interval of 3-5 d between each two courses. The therapeutic efficacy was analyzed after 1, 2 and 3 treatment courses respectively. Results: With the increase of treatment course, the markedly effective rate and total effective rate were also increasing. Of the 43 subjects after 3 treatment courses, the epidermal type had the highest markedly effective rate and total effective rate, then it's the subtype IV of the mixed type and dermal type, and the subtype III of the mixed type had the lowest markedly effective rate and total effective rate. Conclusion: Acupuncture plus auricular point sticking is effective and safe in treating melasma, but different types have different therapeutic efficacies. © 2013 Shanghai Research Institute of Acupuncture and Meridian and Springer-Verlag Berlin Heidelberg. Source

Discover hidden collaborations